Open account
Sign up/Log in
OUTLOOK THERAPEUTICS® ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF $5.0 MILLION
Reuters · 04/15 20:15
OUTLOOK THERAPEUTICS - FILES PROSPECTUS SUPPLEMENT RELATED TO OFFER, SALE OF UP TO $93.7 MLN OF COMMON STOCK THAT MAY BE SOLD UNDER SALES AGREEMENT
Reuters · 04/12 20:30
GREAT POINT PARTNERS, LLC REPORTS 9.99% PASSIVE STAKE IN OUTLOOK THERAPEUTICS AS OF APRIL 1- SEC FILING
Reuters · 04/08 20:13
OUTLOOK THERAPEUTICS INC - ON APRIL 1, RECEIVED WRITTEN NOTICE FROM NASDAQ INFORMING COMPANY THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE
Reuters · 04/02 20:17
BUZZ-U.S. STOCKS ON THE MOVE-Reddit, Alphabet, Tesla
The blue-chip Dow and the benchmark S&P 500 eased on Friday, but are still on track for strong weekly gains. Investors cheered the Federal Reserve's rate-easing stance. Reddit, Alphabet and Tesla were among the biggest losers on Wall Street. The Dow Jones Industrial Average was down 0.46% and the Nasdaq Composite was up.
Reuters · 03/22 17:59
BUZZ-U.S. STOCKS ON THE MOVE-Best Buy, Summit Midstream, Outlook Therapeutics
Wall Street's main stock indexes struggle for direction on Friday. Dow Jones Industrial Average down 0.43% but on track for strong weekly gains. Top three S&P 500 percentage gainers: Fedex Corp, Nvidia, Outlook Therapeutics. Best Buy, Summit Midstream, Tesla among the top U.S. Stocks on the move.
Reuters · 03/22 16:15
BUZZ-Outlook Therapeutics soars as EU drug regulator backs its eye disease drug
Outlook Therapeutics shares rise 35.6% to $9.58 after EU drug regulator backs its eye disease drug. European Commission expected to make a decision on drug's approval within 67 days. Outlook's drug is for a type of eye disease called wet age-related macular degeneration.
Reuters · 03/22 14:09
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Outlook Therapeutics, Inc. Is working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU. The company has closed its previously announced private placement for $60 million in gross proceeds. Outlook has the potential to receive additional gross proceeds of up to $99 million.
Barchart · 03/18 16:10
Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLKW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLKW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading OTLKW stock methods without spending real money on the virtual paper trading platform.